ARGON-BASED INHALABLE GASEOUS MEDICAMENT AGAINST PERIPHERAL ORGAN DEFICIENCIES OR FAILURES
    37.
    发明申请
    ARGON-BASED INHALABLE GASEOUS MEDICAMENT AGAINST PERIPHERAL ORGAN DEFICIENCIES OR FAILURES 审中-公开
    基于ARGON的耐气候药物对外围器官缺陷或失败

    公开(公告)号:US20130039993A1

    公开(公告)日:2013-02-14

    申请号:US13576242

    申请日:2011-01-21

    Applicant: Marc Lemaire

    Inventor: Marc Lemaire

    CPC classification number: A61K33/00 A61K2300/00

    Abstract: The invention relates to a gaseous composition containing an effective amount of argon gas for use, by inhalation, in preventing or treating a deficiency or failure of at least one peripheral organ in a patient. Preferably, it contains between 15 and 80% by volume of argon, and oxygen, preferably at least 21% by volume of oxygen. The organ deficiency or failure thus treated is transient, preferably from less than one hour to a plurality of days or weeks, or definitive. The organ concerned may be the liver, the kidneys or the lungs.

    Abstract translation: 本发明涉及含有有效量的氩气的气体组合物,用于通过吸入用于预防或治疗患者中至少一种周围器官的缺陷或衰竭。 优选地,其含有15至80体积%的氩气和氧气,优选至少21体积%的氧气。 如此治疗的器官缺乏或失败是短暂的,优选从少于1小时到多天或几周或确定。 有关器官可能是肝脏,肾脏或肺部。

    ARGON-BASED INHALABLE GASEOUS MEDICINAL PRODUCT FOR THE TREATMENT OF NEUROINTOXICATIONS
    39.
    发明申请
    ARGON-BASED INHALABLE GASEOUS MEDICINAL PRODUCT FOR THE TREATMENT OF NEUROINTOXICATIONS 审中-公开
    用于治疗神经营养因子的基于ARGON的吸入性药物产品

    公开(公告)号:US20110086107A1

    公开(公告)日:2011-04-14

    申请号:US12969190

    申请日:2010-12-15

    CPC classification number: A61K33/00

    Abstract: The invention relates to the use of argon gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the functioning of dopamine-, glutamate-, serotonin-, acetylcholine-, taurine-, GABA- and/or noradrenalin-mediated neurotransmission systems. Preferably, the proportion by volume of argon in the gaseous medicinal product is between 15 and 80%. The neurointoxication is chosen from excitotoxicities engendering a state of addiction, acute cerebral accidents, neurodegenerative diseases, and psychiatric or neurological pathologies, in particular anxiety conditions, psychotic conditions, in particular schizophrenia, and epilepsy in its various forms.

    Abstract translation: 本发明涉及使用氩气来生产旨在预防或治疗人类神经毒素的全部或部分可吸入药物。 药用产品含有有效比例的氩气,并且作用于至少一种脑受体,以调节多巴胺,谷氨酸,5-羟色胺,乙酰胆碱,牛磺酸,GABA和/或去甲肾上腺素介导的神经传递系统的功能。 优选地,气态医药产品中的氩气体积比例为15-80%。 神经排毒选自产生成瘾状态,急性脑意外,神经变性疾病,精神病学或神经病理学,特别是焦虑症,精神病状况,特别是精神分裂症和各种形式的癫痫的兴奋性毒性。

    Inhalable Gaseous Medicament Based On Xenon And Nitrous Oxide
    40.
    发明申请
    Inhalable Gaseous Medicament Based On Xenon And Nitrous Oxide 审中-公开
    基于氙气和一氧化二氮的可吸入气体药物

    公开(公告)号:US20090252816A1

    公开(公告)日:2009-10-08

    申请号:US12417087

    申请日:2009-04-02

    CPC classification number: A61K33/00 A61K2300/00

    Abstract: The invention concerns the use of a gaseous mixture containing gas xenon and gas nitrous oxide, and advantageously oxygen, for making all or part of an inhalable medicine for preventing or treating neurointoxication in a human. The xenon/nitrous oxide mixture of the invention acts on one or more cerebral receptors to reduce the release and/or the effects of dopamine, glutamate, serotonin, taurin, GABA, noradrenaline and/or any other neurotransmitter. The proportion by volume of xenon of the mixture ranges between 5 and 45%, and the proportion by volume of nitrous oxide ranges between 10 and 50%, the balance is preferably oxygen.

    Abstract translation: 本发明涉及使用含有气体氙气和一氧化二氮气体以及有利地为氧气的气体混合物,用于制备用于预防或治疗人类神经毒素的全部或部分可吸入药物。 本发明的氙/一氧化二氮混合物作用于一种或多种脑受体,以减少多巴胺,谷氨酸,血清素,牛磺酸,GABA,去甲肾上腺素和/或任何其他神经递质的释放和/或作用。 混合物的氙的体积比例为5〜45%,一氧化二氮的体积比为10〜50%,余量优选为氧。

Patent Agency Ranking